Page 8 - Nasdaq Ymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq ymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Ymab Today - Breaking & Trending Today

Y-mAbs Announces Complete Response Letter for Omburtamab

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical. ....

New York , United States , Globe Newswirey Mabs Therapeutics Inc , Y Mabs Therapeutics Inc , Drug Administration , Abs Therapeutics , Biologics License Application , Oncologic Drugs Advisory Committee Meeting , Thomas Gad , Interim Chief Executive , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Y Mabs Therapeutics , Nasdaq Ymab ,

Mirae Asset Global Investments Co. Ltd. Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,186 shares of the company’s stock, valued at approximately $169,000. Other hedge […] ....

United States , Dekabank Deutsche Girozentrale , Morgan Stanley , Kempen Co , Y Mabs Therapeutics Inc , Financial Corp , Connor Clark Lunn Investment Management Ltd , Exchange Commission , Jpmorgan Chase Co , Mirae Asset Global Investments Co , Canaccord Genuity Group , Mirae Asset Global Investments , Y Mabs Therapeutics , Get Rating , Bank Deutsche Girozentrale , Lunn Investment Management , Strs Ohio , Abs Therapeutics , Visit Holdingschannel , Y Mabs Therapeutics Daily , Nasdaq Ymab , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical. ....

New York , United States , Globe Newswirey Mabs Therapeutics Inc , Oncologic Drugs Advisory Committee , Y Mabs Therapeutics Inc , Drug Administration , Advisory Committee , Abs Therapeutics , Thomas Gad , Interim Chief Executive , Biologic License Application , Priority Review , Prescription Drug User Fee Act , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Y Mabs Therapeutics , Nasdaq Ymab ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among […] ....

United States , Y Mabs Therapeutics Company Profile Get Rating , Polar Capital Holdings Plc , Y Mabs Therapeutics Inc , Blackrock Inc , Dimensional Fund Advisors , Y Mabs Therapeutics , Get Rating , Capital Holdings Plc , Street Corp , Abs Therapeutics , Abs Therapeutics Company Profile , Nasdaq Ymab ,

Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $31.60

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price […] ....

United States , Hong Kong , Dekabank Deutsche Girozentrale , Y Mabs Therapeutics Company Profile Get Rating , Y Mabs Therapeutics Inc , Hong Kong Ltd , Royal Bank , Y Mabs Therapeutics , Get Rating , Marketbeat Ratings , Abs Therapeutics , Kong Ltd , Bank Deutsche Girozentrale , Abs Therapeutics Company Profile , Nasdaq Ymab ,